MedTrace Logo

A Study to Assess the Safety and Pharmacokinetics of Inhaled Doses of GSK233705 and GW642444 in Healthy Subjects.

NCT00671216 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 16

Last updated 2017-10-04

No results posted yet for this study

Summary

GW642444 and GSK233705 are in development for treatment of Chronic Obstructive Pulmonary Disease. Development of these two inhaled drugs as a combination therapy would have potential for improved patient benefit as they both work through different mechanisms and the combined bronchodilatory effect might be additive. This study will look at the this combination, for the first time, in healthy subjects.

Conditions

  • Pulmonary Disease, Chronic Obstructive

Interventions

DRUG

GSK233705

Subjects will receive 200 (mcg) microgram once daily as a single dose

DRUG

GW642444

Subjects will receive 50 mcg once daily as a single dose

DRUG

GSK233705 and GW642444

Subjects will receive combination of GSK233705 200 mcg and GW642444 50 mcg as a single oral dose

DRUG

Placebo

Placebo matching study medication will be inhaled by subjects

Sponsors & Collaborators

Principal Investigators

  • GSK Clinical Trials · GlaxoSmithKline

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
CROSSOVER

Eligibility

Min Age
18 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2008-05-20
Primary Completion
2008-07-07
Completion
2008-07-07

Countries

  • United Kingdom

Study Locations

More Related Trials

Entities

Drugs
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00671216 on ClinicalTrials.gov